The problem is that pain is also information
A triple-peptide blend, known as Coremend, containing TB-500 (25mg), BPC-157 (10mg), and KPV (10mg) 45mg total per vial
These characteristics fundamentally distinguish the peptide fragment from full-length human growth hormone therapy
Rather than engaging a single high-affinity receptor, the pentadecapeptide modulates multiple intersecting cellular pathways including nitric oxide system signalling, growth-factor receptor expression (notably VEGF receptor 2 and growth-hormone receptor), dopamine and serotonin pathway markers, and angiogenic factor regulation
Because the compound is unproven in people and material sold as a research chemical is not manufactured to pharmaceutical standards, the full profile of potential effects is uncharacterised